Vanguard Group Inc Neurocrine Biosciences Inc Put Options Transaction History
Vanguard Group Inc
- $5.46 Trillion
- Q3 2024
Put Options
0 transactions
| Quarter | Operation | Price Per put | puts change | puts Held | SEC Form |
|---|
Others Institutions Holding NBIX
# of Institutions
626Shares Held
94MCall Options Held
632KPut Options Held
621K-
Black Rock Inc. New York, NY14.2MShares$1.94 Billion0.04% of portfolio
-
State Street Corp Boston, MA5.15MShares$706 Million0.02% of portfolio
-
Jim Simons Renaissance Technologies LLC | New York, Ny2.57MShares$353 Million0.47% of portfolio
-
Bellevue Group Ag Kuesnacht, V81.86MShares$255 Million3.62% of portfolio
-
Geode Capital Management, LLC Boston, MA1.86MShares$255 Million0.02% of portfolio
About NEUROCRINE BIOSCIENCES INC
- Ticker NBIX
- Exchange NASDAQ
- Sector Healthcare
- Industry Drug Manufacturers—Specialty & Generic
- Shares Outstandng 95,639,296
- Market Cap $13.1B
- Description
- Neurocrine Biosciences, Inc. discovers, develops, and markets pharmaceuticals for neurological, endocrine, and psychiatric disorders. The company's portfolio includes treatments for tardive dyskinesia, Parkinson's disease, endometriosis, and uterine fibroids, as well as clinical programs in various therapeutic areas. Its lead asset is INGREZZA, ...